Dr. Gaston De Serres is an epidemiologist practitioner at the l’Institut national de santé publique du Québec and a regular researcher in the Infectious and Immune Disease Axis at the CHU de Québec-Laval University. He is a full professor in epidemiology in the Department of social and preventive medicine at Laval University where he has been teaching since 1997. He is chief physician of the scientific immunization group (SIG) of the Institut national de santé publique du Québec and an active member of the Comité sur l’immunisation du Québec (CIQ).

Dr. De Serre works on the control and prevention of infectious diseases, with a focus on diseases that are avoidable through vaccination and on respiratory diseases. His research work is on the epidemiology of diseases that are preventable through vaccination and the efficacy of vaccinations used in routine programs, and in particular, on the efficacy of the influenza vaccine.

2400, avenue d'Estimauville, 3e étage
Québec, Québec
Canada G1E 7G9
+1 418-650-5115, extension 6274
+1 418-666-2776
gaston.de-serres@crchudeq... Gaston.DeSerres@inspq.qc....

Latest news

397 entries « ‹ 2 of 40 › »

Carazo S, Skowronski DM, Brisson M, Barkati S, Sauvageau C, Brousseau N, Gilca R, Fafard J, Talbot D, Ouakki M, Gilca V, Carignan A, Deceuninck G, De Wals P, De Serres G

Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study

Journal Article

Lancet Infect Dis, 23 (1), 2023.

Abstract | Links:

Nasreen S, Febriani Y, Velásquez García HA, Zhang G, Tadrous M, Buchan SA, Righolt CH, Mahmud SM, Janjua NZ, Krajden M, De Serres G, Kwong JC

Effectiveness of Coronavirus Disease 2019 Vaccines Against Hospitalization and Death in Canada: A Multiprovincial, Test-Negative Design Study

Journal Article

Clin Infect Dis, 76 (4), 2023.

Abstract | Links:

Longtin Y, Parkes LO, Charest H, Rajarison S, Zaharatos GJ, Fafard J, Roger M, De Serres G

Persistence of infectivity in elderly individuals diagnosed with severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection 10 days after onset of symptoms: A cross-sectional study

Journal Article

Infect Control Hosp Epidemiol, 44 (4), 2023.

Abstract | Links:

Nantel S, Bourdin B, Adams K, Carbonneau J, Rabezanahary H, Hamelin MÈ, McCormack D, Savard P, Longtin Y, Cheng MP, De Serres G, Corbeil J, Gilca V, Baz M, Boivin G, Quach C, Decaluwe H

Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine

Journal Article

Front Immunol, 13 , 2022.

Abstract | Links:

Tauzin A, Gong SY, Chatterjee D, Ding S, Painter MM, Goel RR, Beaudoin-Bussières G, Marchitto L, Boutin M, Laumaea A, Okeny J, Gendron-Lepage G, Bourassa C, Medjahed H, Goyette G, Williams JC, Bo Y, Gokool L, Morrisseau C, Arlotto P, Bazin R, Fafard J, Tremblay C, Kaufmann DE, De Serres G, Richard J, Côté M, Duerr R, Martel-Laferrière V, Greenplate AR, Wherry EJ, Finzi A

A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses

Journal Article

Cell Rep, 41 (4), 2022.

Abstract | Links:

Carazo S, Skowronski DM, Brisson M, Sauvageau C, Brousseau N, Gilca R, Ouakki M, Barkati S, Fafard J, Talbot D, Gilca V, Deceuninck G, Garenc C, Carignan A, De Wals P, De Serres G

Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, Canada

Journal Article

JAMA Netw Open, 5 (10), 2022.

Abstract | Links:

Kim S, Chuang ES, Sabaiduc S, Olsha R, Kaweski SE, Zelyas N, Gubbay JB, Jassem AN, Charest H, De Serres G, Dickinson JA, Skowronski DM

Influenza vaccine effectiveness against A(H3N2) during the delayed 2021/22 epidemic in Canada

Journal Article

Euro Surveill, 27 (38), 2022.

Abstract | Links:

Carazo S, Villeneuve J, Laliberté D, Longtin Y, Talbot D, Martin R, Denis G, Ducharme F, Paquet-Bolduc B, Anctil G, Hegg-Deloye S, De Serres G

Risk and protective factors for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection among healthcare workers: A test-negative case-control study in Québec, Canada

Journal Article

Infect Control Hosp Epidemiol, 2022.

Abstract | Links:

Carazo S, Skowronski DM, Laforce R, Talbot D, Falcone EL, Laliberté D, Denis G, Deshaies P, Hegg-Deloye S, De Serres G

Physical, Psychological, and Cognitive Profile of Post-COVID Conditions in Healthcare Workers, Quebec, Canada

Journal Article

Open Forum Infect Dis, 9 (8), 2022.

Abstract | Links:

Sadarangani M, Soe P, Shulha HP, Valiquette L, Vanderkooi OG, Kellner JD, Muller MP, Top KA, Isenor JE, McGeer A, Irvine M, De Serres G, Marty K, Bettinger JA,

Safety of COVID-19 vaccines in pregnancy: a Canadian National Vaccine Safety (CANVAS) network cohort study

Journal Article

Lancet Infect Dis, 22 (11), 2022.

Abstract | Links:

397 entries « ‹ 2 of 40 › »
Signaler des ajouts ou des modifications

Active projects

  • (SI03 QC03) Special Immunization Clinic Network (SIC) to investigate vaccine safety issues: Optimizing the clinical management of patients with contraindication to vaccination ..., from 2019-04-01 to 2024-03-31
  • Enquête sérologique chez les travailleurs de la santé qui rapportent n’avoir jamais fait la COVID-19 depuis le début de la pandémie, from 2023-04-20 to 2023-12-31
  • Fréquence et séquelles fonctionnelles du syndrome post-COVID-19 chez les travailleurs de la santé , from 2023-03-02 to 2025-07-31
  • HPV vaccination effectiveness in a Canadian setting, 12 years after implementation: are we on the road to eliminate cervical, from 2020-10-01 to 2024-09-30
  • SI05 QC03, Optimizing the clinical management of patients with adverse events following COVID-19 vaccination and potential contraindications to vaccination in the Special Immunization Clinic Network, from 2021-11-01 to 2024-03-31
  • SI06 QC03, Optimizing the clinical management of patients with adverse events following COVID-19 vaccination and potential contraindications to vaccination in the Special Immunization Clinic Network, from 2021-04-01 to 2023-10-31
  • The test-negative design for the estimation of COVID-19 vaccine effectiveness: design evaluation and development of statistical methods in the evolving context, from 2022-10-01 to 2025-09-30

Recently finished projects

  • (CV04 QC03) CANVAS Network - Surveillance of adverse events following immunization among children and adults immunized with the influenza vaccine, from 2017-06-01 to 2022-03-31
  • Canadian Immunization Research Network, from 2014-06-01 to 2021-12-31
  • Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) COVID-19 Vaccine Post-Market Studies, from 2020-12-01 to 2023-06-30
  • CV07 QC03 Canadian National Vaccine Safety (CANVAS) network: Surveillance of Adverse Events Following Immunization among children and adults Immunized with the COVID-19 Vaccine, from 2021-04-01 to 2023-09-30
  • Efficacité des vaccins contre la CVOID-19, from 2021-04-20 to 2022-06-30
  • Identification de stratégies pour outiller les gestionnaires des milieux de soins pour l’application optimale des mesures de prévention et contrôle des infections chez les travailleurs de la santé durant la pandémie de COVID-19, from 2021-01-01 to 2022-02-08
  • Prize 202203PJT - The test-negative design for the estimation of COVID-19 vaccine effectiveness: design evaluation and development of statistical methods in the evolving context, from 2022-10-01 to 2023-03-31
  • Surveillance des manifestations cliniques survenant après la vaccination contre la COVID-19 au Québec, from 2020-12-01 to 2021-12-31
Data provided by the Université Laval research projects registery